Undifferentiated Pleomorphic Sarcoma Clinical Trials

5 recruiting

Undifferentiated Pleomorphic Sarcoma Trials at a Glance

9 actively recruiting trials for undifferentiated pleomorphic sarcoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Oslo, Boston, and Aurora. Lead sponsors running undifferentiated pleomorphic sarcoma studies include National Cancer Institute (NCI), Oslo University Hospital, and Matthew Bucknor.

Browse undifferentiated pleomorphic sarcoma trials by phase

Treatments under study

About Undifferentiated Pleomorphic Sarcoma Clinical Trials

Looking for clinical trials for Undifferentiated Pleomorphic Sarcoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Undifferentiated Pleomorphic Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Undifferentiated Pleomorphic Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled248 locationsNCT06422806
Recruiting
Phase 2

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

SarcomaAlveolar Soft Part SarcomaUndifferentiated Pleomorphic Sarcoma+1 more
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT04332874
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Not Applicable

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

AngiosarcomaOsteosarcomaEwing Sarcoma+4 more
Centre Leon Berard168 enrolled16 locationsNCT04055220
Recruiting
Phase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSynovial Sarcomas+7 more
Oslo University Hospital40 enrolled2 locationsNCT07173972
Recruiting
Phase 2

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Soft Tissue Sarcoma AdultLeiomyosarcomaSynovial Sarcomas+6 more
Oslo University Hospital110 enrolled4 locationsNCT07169344
Recruiting
Not Applicable

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma
Matthew Bucknor20 enrolled1 locationNCT04123535
Recruiting
Phase 2

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

AngiosarcomaLeiomyosarcomaSynovial Sarcoma+8 more
HRYZ Biotech Co.148 enrolled1 locationNCT06277154
Recruiting
Phase 2

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

AngiosarcomaSoft Tissue Sarcoma AdultUndifferentiated Pleomorphic Sarcoma
Niels Junker80 enrolled4 locationsNCT05961761